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Abstract
Background: Osteoporosis and bone fractures seem to be higher in HIV-infected Patients compared to the general
populations. Moreover, bone turnover markers are increased in patients on antiretroviral therapy and vitamin D
deficiency is prevalent in HIV-infected patients. However, the influence of per oral cholecalciferol on bone metabolism
in HIV infected patients is not well understood.
Methods: We measured the bone turnover markers in 96 HIV-infected patients: Bone specific alkaline phosphatase (BSAP),
Pyridinoline (PYR), Desoxypyridinoline (DPD) and 25-OH vitamin D. If 25-OH vitamin D was below 75 nnol/L (87/96 patients),
300000 IU cholecalciferol was given per os. 25OH-vitamin D and bone turn over markers were determinded 3 month later.
25 OH-vitamin D was corrected for circannual rythm

y
0 ¼ y þ 17:875  sin ð2 π365  day þ 2:06Þ

, whereas bone turnover
markers were not corrected. The paired students t-Test was used to compare the two periods. No calcium supplementation
or biphosphonate therapy was given.
Results: Corrected 25OH-vitamin D levels increased significantly after supplementation (42.7 ± 26.61 vs. 52.85 ± 21.8 nmol/L,
p < 0.001). After supplementation, bone turnover markers were significantly lower. The values decreased for BSAP from
21.31 ± 14.32 to 17.53 ± 8.17 μg/L (p < 0.001), PYR from 74.57 ± 36.83 to 54.82 ± 21.43 nmol/mmol creatinine (p < 0.001) and
DPD from 15.17 ± 8.34 to 12.61 ± 5.02 nmol/mmol creatinine (p = 0.01).
Conclusions: After per oral substitution with cholecalciferol, bone formation as well as bone resorption markers decreased
significant. We postulate a protective effect on bone structure with cholecalciferol supplementation.
Background
With the decline of opportunistic infections as conse-
quence of antiretroviral therapy, life expectancy of HIV
infected patients has prolonged remarkably [1]. In this
newer era, in which HIV-infection is considered as a
chronic, treatable disease, the focus on long time side ef-
fects of antiretroviral treatment as well as issues related
to aging, partly aggravated by the HIV-infection itself,
will become more and more important.
Recognized as a growing epidemic in the older, non
HIV infected population, osteoporosis has become of
particular interest to physicians treating HIV patients as
well [2].
In HIV patients, an increased incidences of bone frac-
tures has been observed [3], and it has been suggested
that vitamin D deficiency [4,5] and low bone mineral
density [6,7] are important pathogenic factors. Efavirenz
has been shown to decrease vitamin D levels [5,8], and
antiretroviral treatment was associated with increased
bone turnover [9] as well as decreases in bone mineral
density [10,11].
Levels of vitamin D are influenced by sunlight expos-
ure and follow a seasonal rhythm [12]. Supplementation
of low vitamin D levels has been widely adopted in HIV-
care, but the benefits with respect to bone turn over,
bone mineral density or fracture rate has not been
clearly demonstrated. Most studies in non-HIV patients
with osteoporosis have combined cholecalciferol and cal-
cium supplementation [13,14]. A decrease in bone re-
sorption as well as preservation of bone mineral density
has been observed with a combination of cholecalciferol
and calcium, but not with calcium supplementation
alone [15].
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Low levels of vitamin D in HIV-patients compared to
the general population are well described. However it
is still not understood if this is due to the HIV infection
itself or to traditional risk factors. Therefore, we com-
pared vitamin D levels not with the general population,
but with HBV and HCV monoinfected patients, postu-
lating similar living conditions as well as chronic inflam-
matory status. Moreover, osteoporosis and low vitamin
D level has also described in hepatitis B and C patients
[16-19]. 25OH-vitamin D levels may also influence treat-
ment outcome in Hepatitis C patients [20].
In patients with low 25OH-vitamin D levels, we sup-
plemented cholecalciferol and controlled bone turnover
markers before and after supplementation. We choose a
high dose pulse therapy primarily to limit pill burden, as
it can be given at visit in the outpatient clinic.
Methods
Patients were recruited in the outpatient infectious dis-
ease clinic of Kantonsspital Olten. Baseline characters
are presented in Tables 1 and 2. Patients were excluded
if a start or switch in ART had been performed in the
last six months, as this may interfere with 25OH-
Vitamin D levels and bone turnover. In patients with ur-
gent need of antiretroviral therapy, no intervention data
were collected for the same reason. Patients with Hepa-
titis monoinfection were excluded if treated with inter-
feron. Dexa scans and nutrional data collection were not
performed. At the follow up visit, questionnaire con-
cerning overall physical health including specific ques-
tioning pain (bone fractures, nephrolitiasis) or nausea was
filled out. Blood testing including liver, renal, metabolic
and immunological parameters was also performed.
25OH-vitamin D, bone specific alkaline phosphatase
(BASP) were measured in serum, pyridinoline (PYR) and
desoxypyrindinoline (DPD) crosslinks were measured in
first morning urine. Patients with 25OH-vitamin D <75
nmol/L [= 30 ng/mL] were substituted with 300000 IU
cholecalciferol orally. 25OH-vitamin D, BSAP and cross-
links were controlled 3 month after supplementation.
25OH-vitamin D was corrected for circannual rythm
h
y
0 ¼ yþ 17:875  sin 2 π365  dayþ 2:06
 i
[21], bone turn-
over markers were not corrected. According to the method
published by Bolland who showed that the concentration of
25OH-vitamin D follows a sine curve, we corrected the
values for: baseline + amplitude × sine (angular fre-
quency × day of the year + phase shift). Angular fre-
quency was 2 × π/365, and the phase shift is the
translation from x axis. As the minimum/maximum con-
centrations were in february resp. august, phase shift was
calculated accordingly. Amplitude was calculated from
minimum and maximum monthly mean values (before
supplementation).
No calcium supplementation or biphosphonate ther-
apy was given. Paired students t-test was used to com-
pare the two periods. Unpaired Students t test was used
to compare 25OH-vitamin D levels between HIV and
HCV/HBV patients.
Response to cholecalciferol was defined as ≥10% re-
duction in one or both of the two crosslinks. Calculation
of factors that favour response was made by Chi-Square
test for 2×2 tables. Correlations were made be linear re-
gression with a significance level of 95%.
Ethics approval
Treatment with cholecalciferol in patients with hypovita-
minosis was considered as standard care, and decided by
the attendant physician. So under Swiss regulations, this
study did not need formal ethical approval.
Results
Differences between Hepatitis and HIV infected patients
25OH-vitamin D, BSAP and crosslinks were measured
in 96 HIV infected patients. 25OH-vitamin D levels were
compared with 70 HBV or HCV monoinfected patients.
Baseline characters are shown in Tables 1 and 2. No differ-
ence in age between HIV and Hepatitis patients (42.5 ± 9.1
vs. 42.8 ± 11.2 years, p = 0.9) or gender was present (39/70
vs. 54/96 male patients, p = 0.9). 47/70 Hepatitis patients
had an HCV infection. No significant difference in 25OH-
vitamin D levels could be found between HIV and non
Table 1 Baseline characteristics HIV patients
ART (%) No ART(%) p-value TDF (%) No TDF(%) p-value PI NNRTI
Men 40 (54) 15 (65) 0.38 26 (48) 14 (73) p = 0.054 21 (65) 17 (42) 0.03
Women 33 (36) 8 (35) 28 (52) 5 (27) 10 (35) 23 (58)
Total 73 (76) 23 (24) 54 (74) 19 (26) 32 (44) 40 (56)
Age ± SD 43 ± 9 43 ± 9 0.74 42 ± 10 43 ± 11 p = 0.84 44 ± 9 41 ± 8 p = 0.08
CD4 < 200 10 (50) 10 (50) 0.003 6 (60) 4 (40) p = 0.4 6 (60) 4 (40) p = 0.3
CD4200-350 23 (92) 2 (8) 16 (76) 5 (24) 7 (30) 15 (70)
CD4 > 350 40 (78) 11 (22) 32 (80) 8 (20) 18 (45) 21 (55)
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HIV-patients (45.3 ± 29.7 vs. 48.8 ± 22.1 nmol/L, p = 0.4)
(see Figure 1).
Correlations between 25OH-vitamin D and bone turn over
markers
No correlations between 25OH-vitamin D levels prior to
substitution and bone turn over levels could be found. For
BSAP, r value was -0.043 ± 0,045 p = 0.34. Also for
bone resorption markers, no correlation was present
with r value of 0.001 ± 0.12, p = 0.99 for PYR and -0.02 ±
0.03, p = 0.54 for DPD (See Additional file 1: Figure S1a).
Substitution with cholecalciferol
87/96 (90.6%) of the patients had a 25OH vitamin D
level < 75 nmol/l, 10/96 (10.4%) were below 25 nmol/L.
Four patients had an urgent indication for antiretroviral
therapy and were not included for control after substitu-
tion, as ART can influence vitamin D as well as bone
turn over markers. 6 patients did not provide urine sam-
ples 3 month after substitution. In 77 patients analysis of
the effect of cholecalciferol substitution could be done. 3
month after substitution, corrected 25OH-vitamin D
levels were significantly higher (42.7 ± 26.61 vs. 52.85 ±
21.8 nmol/L, p < 0.001). No patient had 25OH-vitamin
D level in toxic range (>250 nmol/L) after substitution
(See Figure 2).
Bone turnover markers
Bone turnover markers fell significantly after substitutions.
The bone formation marker BSAP fell from 21.31 ± 14.32
to 17.53 ± 8.17 μg/L (p < 0.001). Normal value for BSAP
is < 14.3 μg/L pre- and 22.4 μg/L postmenopausal.
For bone resorption markers, PYR decreased from
74.57 ± 36.83 to 54.82 ± 21.43 nmol/mmol creatinine
(p < 0.001) and DPD from 15.17 ± 8.34 to 12.61 ± 5.02
nmol/mmol creatinine (p = 0.01) (See Figures 2 and 3).
Factors for response
We defined response to cholecalciferol as at least 10%
reduction in either PYR or DPD. This is arbitrary but no
data exist regarding response to cholecalciferol and bone
turnover markers. 52/77 (67.5%)patients did respond.
We then correlated response with gender, HCV-infection,
antiretroviral treatment, TDF-, PI- and NNRTI use, age,
african descent, BMI < 21, smoker and 25OH-vitamin D
level < 30 nmol/L. Antiretroviral treatment was correlated
with better response to cholecalciferol (OR 2.76, CI 1.58 –
4.53, p = 0.002), however the low number of patients
without antiretroviral treatment limits the statistical value
of this data. For other factors, no significance could be
observed (see Table 3).
Discussion
Low bone mineral density (BMD) as well as insufficiency
fractures are more common in HIV-patients compared
to the general population [3,11,22]. Vitamin D deficiency
is believed to be more frequent in HIV-patients [4,23].
We did not compare our patients with the general popula-
tion, but with patients with a hepatitis B or C mono-
infection and did not find a difference in vitamin D levels.
Although it is known that Efavirenz can decrease vitamin
D levels [8], life circumstances may be a more important
factor for low vitamin D level than HIV-infection itself.
It is known that antiretroviral therapy increases bone
turn over markers [9]. In accordance to Welz [8], we did
not find a direct correlation between bone turnover
markers and 25OH-vitamin D leves at baseline, but a
significant decrease after supplementation. Results of
cholecalciferol supplementation on bone turnover are
conflicting. Contrary to our results, two recent publica-
tions showed an increase of BTM after high dose chole-
calciferol supplementation [24,25], but these results
were seen primarily in the first weeks after interven-
tion, while at 16 weeks and one year, supplementation
resulted in a decrease in bone turnover markers [26,27].
We did not measure or supplement calcium intake. Differ-
ent results on BTM could be due to different calcium
uptake, as the positive effect of active 1, 25OH vitamin D




Men 55 (57) 41(57)
0.96
Women 41 (43) 31 (43)
Total 96 72
Age 43 ± 9 43 ± 12 0.75
Opiat consumption/
substitution
31 (32) 23 (32) 0.82
Diabetes mellitus 5 (5) 2 (3) 0.65
HCV infection 36 (37) 50 (69) <0.001
Figure 1 Differences between HIV and Hepatitis monoinfected
patients.
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results in an increased calcium uptake, while the direct
effect of vitamin D on osteoclasts and osteoblasts will
enhance bone resorption and decrease bone formation
[28]. In HIV-negative patients, most studies have been
done in high risk populations with combined calcium and
cholecalciferol supplementation [29]. These studies show a
benefit with a reduction in fracture rate of 20% in patients
in whom a target value of > 50 nmol/L 25OH-vitamin D
could be achieved [30]. It is suggested that 25OH-vitamin
D levels should even be supplemented to >75 nmol/L [31].
Even if the results of studies regarding fractures rate in
HIV-patients yielded conflicting results and the effect of
cholecalciferol is uncertain [32-36], we actually suggest
cholecalciferol supplementation. We observed a decrease
in bone resorption as well as bone formation markers
3 month after supplementation. A correlation between
bone formation and bone resorption markers has be
observed in other studies too [9,37]. We hypothesize
Figure 2 Vitamin D and BSAP before and after supplementation.
Figure 3 DPD and PYR before and after supplementation.
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that vitamin D may limit bone resorption, leading to a
decrease in compensatory bone formation.
We used a high dose of cholecalciferol as “pulse ther-
apy”. This increase in 25OH vitamin D was significant
but only about two third of that found in a recent study
using 300000 IU intramuscularly [25]. This marked
effect was also seen in another study from Iran [38] but
our results were similar to a study from Australia [39].
High dose pulse therapy with cholecalciferol has previ-
ously been a regularly followed strategy but some au-
thors advocate lower doses on daily base. Two rationales
for daily or weekly cholecalciferol doses have been
proposed. First, vitamin D has also an effect on muscle
[40]. High levels of vitamin D could rapidly improve
muscle function in frail patients in whom coordination
is still reduced, leading to falls and fractures [41]. Sec-
ondly, vitamin D intoxication has been seen with pulse
therapy [42]. Hypersensitivity to vitamin D has been
correlated to mutations in CYP24A1 and these patients
may have elevated vitamin D levels without supple-
mentation [43]. As vitamin D had not been measured
in most patients before supplementation, intoxication
could be due to hypersensitivity rather than to high
doses of cholecalciferol alone. As we only substituted
patients with 25OH-vitamin D deficiency, we think it is
safe to give 300000 IU orally every 6 months. No toxic
effects of vitamin D were observed. Even if life expect-
ancy in HIV patients has markedly improved, frailty is
still not a issue in most HIV-infected patients [44]. We
therefore believe that the effect on muscle function may
not lead to more falls. However, the optimal strategy for
cholecalciferol supplementation has to be defined. Even if
we could observe an increase in 25OH-vitamin D levels,
only about 20% of our patients did reach target value
of 75 nmol/L. Similar results has been shown in HIV
patients given pulse [45] or continues low dose (4000 IU
daily) supplementation [46].
We defined a decrease of ≥ 10% of either one or both
bone resorption markers as response to cholecalciferol.
This is an arbitrary definition but no cut-off values have
been described. Even if we could find a significant over-
all decline in bone turnover markers, only 52/77 patients
had a decrease in bone turnover markers, while 25 had
not. We could not find a correlation with traditional risk
factors or specific antiretroviral drugs and the response
to Vitamin D supplementation in the univariate analyi-
sis. Due to the lack of significance in univariate analysis,
it is in our view inappropriate to perform a multivariate
analysis, as these results cannot be interpreted properly.
The same problem applies to the treated vs. non treated
HIV-patients. Given the low number of patients without
ART, the statistical significance compared to treated
patients should be interpreted with caution. In Non-HIV
patients, the effect of cholecalciferol on bone turnover
markers shows conflicting results. While some studies
show no effect despite benefit on BMD [47], others did
show an amelioration of bone turnover [48,49].
Our study has some limitations. It is a relatively small,
open and not placebo controlled trial, and we did not
measure calcium intake and sun exposure. Even if bone
turnover markers are directly correlated with fracture
rate independently of BMD [50], they do not substitute
for the later. Thus far, we only showed a short term
effect on bone metabolism, while ultimately reduced
fracture rate is the primary endpoint of this medical
intervention. Thus we propose larger, long term studies
including DXA-scans and clinical events.
Conclusion
In summary, we showed that supplementation with high
dose pulse therapy with cholecalciferol in HIV-patients
with low 25OH vitamin D level resulted in a decline of
bone resorption as well as in bone formation markers.
As it has been shown that bone resorption and forma-
tion are linked, we postulate a protective effect on bone
structure by cholecalciferol substitution.






No HCV 27 17
IVDU 23 6
1.91 0.86-4.23 0.08
No IVDU 29 19
Treatment 48 16
2.76 1.58-4.03 0.002
No Treatment 4 9
TDF 36 13
1.61 0.85-3.04 3.04







African descent 12 8
1.34 0.68-2.61 0.4
No african descent 40 17
Age < 40 18 10
0.85 0.44-1.64 0.21
Age > 40 34 15
BMI < 21 7 2
1.52 0.43-5.4 0.48
BMI > 21 45 23
Smoker 32 13
1.29 0.68-2.49 0.42
Non smoker 20 12
Vit D 30-75 nmol/L 38 17
0.97 0.47-2.01 0.92
Vit D < 30 nmol/L 15 7
Total 52 25
*34/36 NNRTI patients received EFV.
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Additional file
Additional file 1: Figure S1a. Correlation between Vitamin D and
bone turnover markers.
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